ReviewCancers2022
An Overview of Pituitary Incidentalomas: Diagnosis, Clinical Features, and Management.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Triple sellar collision lesion: a unique case of pituitary adenoma, Rathke cleft cyst, and xanthogranuloma-case report and systematic review of the literature.Brain tumor pathology · 2025Pooled it
- Staining collagen fibers in pituitary lesions substantially improves the certainty of intraoperative frozen section diagnosis.Pituitary · 2026Article
- Article
- Persistent Rhinosinusitis-Like Symptoms Revealing a Lactotroph Pituitary Neuroendocrine Tumour: A Case Report.Cureus · 2026Article
- BDNF and TNF-α, OCT and VF Parameters in Pituitary Macroadenoma Patients: A 12-Month Prospective Study.International journal of molecular sciences · 2026Observational
- Radiological Differentiation of Pituitary Adenomas From Other Sellar Masses: A Systematic Review.Cureus · 2025Review
- Pituitary incidentaloma: a Pituitary Society international consensus guideline statement.Nature reviews. Endocrinology · 2025Review
- Revisiting Pituitary Incidentalomas: Insights from Prevalence Data and Consensus Recommendations.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Incidental paraganglioma of sella : A case report and literature review.Journal of clinical imaging science · 2025Article
- A Study in Pituitary Neuroendocrine Tumors (PitNETs): Real-Life Data Amid Baseline and Serial CT Scans.Cancers · 2024Article
- A Real-World Longitudinal Study in Non-Functioning Pituitary Incidentalomas: A PRECES Micro-Adenomas Sub-Analysis.Diseases (Basel, Switzerland) · 2024Article
- Headache in patients with non-functioning pituitary adenoma before and after transsphenoidal surgery - a prospective study.Pituitary · 2024Article
- FSH-producing pituitary neuroendocrine tumor as a cause of ovarian hyperstimulation syndrome.Endocrinology, diabetes & metabolism case reports · 2024Article
- Suggestion of Follow-Up Period in Nonfunctioning Pituitary Incidentaloma Based on MRI Characteristics.Brain tumor research and treatment · 2024Article
- Article
- Pituitary macroadenoma: less common neuroimaging features in a common lesion.Radiologia brasileiraArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Pituitary incidentalomas are tumors or mass lesions of the pituitary gland. These are incidentally discovered during imaging studies for symptoms that are not causally related to pituitary diseases. The most common symptom that triggers an examination is headache, and the most common type of pituitary incidentalomas are pituitary neuroendocrine tumors (PitNETs) and Rathke cleft cysts. The existing treatment strategy is controversial; however, surgical resection is recommended in cases of clinically non-functioning PitNETs with optic chiasm compression. In contrast, cystic lesions, such as Rathke cleft cysts, should be followed if the patients are asymptomatic. In this case, MRI and pituitary function tests are recommended every six months to one year; if there is no change, the follow-up period should be extended. The natural history of PitNET is partially known, and the management of pituitary incidentalomas is determined by this history. However, the pathogenesis of PitNET has significantly changed with the new World Health Organization classification, and follow-up is important based on this new classification. Therefore, a high level of evidence-based research is needed to consider treatment guidelines for pituitary incidentalomas in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.